Astra Zeneca has suffered a new setback, according to a press release from the Swedish-British pharmaceutical giant.
Datopotamab deruxtecan (Dato-DXD) – a preparation for the treatment of patients with cancer developed with Japanese Daiichi Sankyo – has, according to a phase-3 study comparing Dato-DXD's effect with the effects of chemotherapy in breast cancer, not shown any statistically confirmed positive effects regarding the patients' lifespan.
Earlier in September, a separate study also did not show any significant impact on survival for lung cancer patients.
Astra Zeneca's share has risen by 18 percent since the turn of the year.
